4.7 Article

Dimer targeting peptide mediated precise and controllable drug delivery by upconversion nanocarriers for breast cancer therapy

期刊

MATERIALS & DESIGN
卷 203, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.matdes.2021.109597

关键词

Near-infrared light control; Upconversion nanoparticle; Epirubicin; targeting peptide; Breast cancer

资金

  1. National Natural Science Foundation of China [81902622, 31900963, 81902996]
  2. Shanghai Science and Technology Innovation Action Plan Hong Kong, Macao, and Taiwan Science and Technology Cooperation Project [20430760100]
  3. Health-Education Joint Research Project of Fujian Province [2019-WJ-22]
  4. Shanghai Pujiang Program [18PJ1409400]

向作者/读者索取更多资源

The study demonstrates the development of a novel upconversion nanocarriers (UCNCs) system for precise and controllable delivery of chemotherapy drugs to breast cancer cells, inhibiting cancer cell proliferation, migration, and invasion effectively.
Breast cancer is one of the leading causes of cancer-related deaths in women. Chemotherapy remains one of the main clinical treatments for breast cancer. However, this therapy has appreciable side effects. Nanoscale carriers, such as metal nanoparticles and liposomes, are being widely utilized as drug delivery vehicles to achieve precise targeting of tumor cells. In this study, we designed a novel upconversion nanocarriers (UCNCs) host-guest com-plexation system based on a photolabile capping-like molecule. UCNCs containing epirubicin (EPI) were grafted with a dimer-targeting peptide via cyclodextrin-adamantine host-guest complexation. After entering breast tumor cells with the guidance of the dimer-targeting peptide, the core of the UCNCs upconverted near-infrared light to ultraviolet light which subsequently triggered the intracellular on-demand release of epirubicin. The precise and efficient delivery and release of epirubicin inside breast cancer cells significantly inhibited cancer cells proliferation, migration, and invasion in vitro and decreased the tumor size in vivo. We believe that this UCNCs system is a promising platform for the precise and controllable delivery of various chemotherapy drugs for clinical cancer treatments. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据